[Thymopentin in the treatment of recurrent condylomata acuminata].
Twelve patients who had been suffering from genital and/or perianal recurrent condyloma acuminatum for a minimum of 5 to a maximum of 24 months, in spite of treatment, were studied from the immunological viewpoint and treated with 50 mg s.c. Thymopentin three times a week for 4 or 6 weeks. Six of the patients were cured at the end of treatment, five after 5 months, and one was not cured. Analysis of the clinico-laboratory data shows a significant agreement between the course of clinical signs and the immunological picture. The various cure stages are probably attributable to the basic immune arrangement which was more impaired in the 5 patients who were cured more slowly and in the non-cured case. In the latter too, however, Thymopentin permitted correcting the balance of the relationship between the various lymphocyte subpopulations.
Ghetti
P
P
Negosanti
M
M
Andriani
G C
GC
Beltrandi
E
E
Maldini
M
M
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001005:Anus Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D003218:Condylomata Acuminata / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D012008:Recurrence; D016305:Thymopentin; D013946:Thymopoietins / Q000008:administration & dosage / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin
La timopentina nel trattamento dei condilomi acuminati recidivanti.